MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Prevalence of Parkinson’s disease and Atypical Parkinsonisms in Colombia: Data from the national health registry 2016-2021

    G. Rincón, J. Torres-García, C. Pantoja-Ruiz, D. Rosselli (Bogotá, Colombia)

    Objective: To estimate prevalence of Parkinson’s Disease (PD) and Atypical Parkinsonisms and characterise the diagnosed population in a country with a development economy Background: The…
  • 2022 International Congress

    Diagnostic algorithm in recessive and sporadic early-onset ataxias

    D. Gasca Saldaña, C. Boll Woehrlen, N. Jaramillo, C. Alaez-Verson (Ciudad de México, Mexico)

    Objective: To develop a diagnostic algorithm that allows to differentiate recessive or sporadic ataxias by the clinical phenotype, biochemical markers and neuroimaging studies of the…
  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    Establishing and validating 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced zebrafish model of Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

    Objective: The current study aims to establish a zebrafish model of PD using MPTP neurotoxin and the validation of the MPTP effect through swimming behavior…
  • 2022 International Congress

    Facial emotion recognition in Parkinson’s disease: the role of executive and affective domains

    A. Siquier, P. Andrés (Palma, Spain)

    Objective: We aimed to explore facial emotion recognition (FER) skills in individuals with Parkinson’s disease (PD) by using a dynamic presentation of emotions across different…
  • 2022 International Congress

    The prevalence of helicobacter pylori in Parkinson’s disease

    N. Mansurova (Tashkent, Uzbekistan)

    Objective: to study the association between helicobacteriosis pylori (HP) and patients with Parkinson's disease Background: Helicobacter pylori is a bacterium associated with gastrointestinal diseases and…
  • 2022 International Congress

    Mimics or multiplicity: two patients with a PSP phenotype and underlying genetic neurodegenerative disorders.

    S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin, Ireland)

    Objective: To describe a two cases of patients presenting with a PSP phenotype and genetic findings consisted with Huntington’s disease (HD) in one case and…
  • 2022 International Congress

    Transcranial magnetic resonance-guided focused ultrasound in Lance-Adams syndrome

    R. Galimova, YU. Sidorova, G. Akhmadeeva, O. Kachemaeva, D. Krekotin, I. Buzaev, N. Muhamadeeva (Ufa, Russian Federation)

    Objective: The objective is to present the first reported case of a patient with post-hypoxic myoclonus (PHM) who underwent noninvasive MR-guided Focused Ultrasound Treatment (MRgFUS).…
  • 2022 International Congress

    A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress

    R. Pahwa, A. Ellenbogen, R. Elble, K. Bankole, T. Dam, J. Fratantonio, J. Gaiha-Rohrbach, M. Qin, S. Garafola, M. Gerbasi, H. Colquhoun (Kansas City, USA)

    Objective: The phase 2b KINETIC 2 trial is a double-blind, randomized, placebo-controlled, dose-response study designed to evaluate SAGE-324/BIIB124 (SAGE-324) for the treatment of patients with…
  • 2022 International Congress

    Smoking and Substantia Nigra Neuron Density in the Presence and Absence of Lewy Pathology

    G. Ross, R. Abbott, H. Petrovitch, J. Duda, J. Uyehara-Lock, K. Masaki, C. Tanner (Honolulu, USA)

    Objective: Our objective is to examine the association of mid-life smoking with post mortem substantia nigra (SN) neuron density in the presence and absence of…
  • 1
  • 2
  • 3
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley